Abolfathi, Z., Couture, J., Vallee, F., Lebel, M., Tanguay, M., and Masson, E. (2004). A pilot study to evaluate
the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. J
Pharm Pharm Sci 7, 345-349.
Afatinib (2018). Afatinib Tablets Interview form [Online]. Available: https://www.boehringeringelheim.ca/sites/ca/files/documents/giotrifpmen.pdf [Accessed].
Alter, P., Herzum, M., Soufi, M., Schaefer, J.R., and Maisch, B. (2006). Cardiotoxicity of 5-fluorouracil.
Cardiovasc Hematol Agents Med Chem 4, 1-5.
Anderson, P.G., Digerness, S.B., Sklar, J.L., and Boor, P.J. (1990). Use of the isolated perfused heart for
evaluation of cardiac toxicity. Toxicol Pathol 18, 497-510.
Antoni, D., Burckel, H., Josset, E., and Noel, G. (2015). Three-dimensional cell culture: a breakthrough in
vivo. Int J Mol Sci 16, 5517-5527.
Aoki, H., Sadoshima, J., and Izumo, S. (2000). Myosin light chain kinase mediates sarcomere organization
during cardiac hypertrophy in vitro. Nat Med 6, 183-188.
Archer, C.R., Sargeant, R., Basak, J., Pilling, J., Barnes, J.R., and Pointon, A. (2018). Characterization and
Validation of a Human 3D Cardiac Microtissue for the Assessment of Changes in Cardiac Pathology.
Sci Rep 8, 10160.
Balza, R.O., Jr., and Misra, R.P. (2006). Role of the serum response factor in regulating contractile apparatus
gene expression and sarcomeric integrity in cardiomyocytes. J Biol Chem 281, 6498-6510.
Banks, M., Crowell, K., Proctor, A., and Jensen, B.C. (2017). Cardiovascular Effects of the MEK Inhibitor,
Trametinib: A Case Report, Literature Review, and Consideration of Mechanism. Cardiovasc
Toxicol 17, 487-493.
Boopathy, G.T.K., and Hong, W. (2019). Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis. Front
Cell Dev Biol 7, 49.
Bowes, J., Brown, A.J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., and Whitebread, S. (2012).
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug
Discov 11, 909-922.
Brown, S.A., Okwuosa, T.M., Barac, A., and Volgman, A.S. (2020). The Role of Angiotensin-Converting
Enzyme Inhibitors and beta-Blockers in Primary Prevention of Cardiac Dysfunction in Breast
Cancer Patients. J Am Heart Assoc 9, e015327.
Burridge, P.W., Li, Y.F., Matsa, E., Wu, H., Ong, S.G., Sharma, A., Holmstrom, A., Chang, A.C., Coronado, M.J.,
Ebert, A.D., Knowles, J.W., Telli, M.L., Witteles, R.M., Blau, H.M., Bernstein, D., Altman, R.B., and
Wu, J.C. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the
predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med 22, 547556.
76
Chen, B., Peng, X., Pentassuglia, L., Lim, C.C., and Sawyer, D.B. (2007). Molecular and cellular mechanisms
of anthracycline cardiotoxicity. Cardiovasc Toxicol 7, 114-121.
Chen, B., Zhong, L., Roush, S.F., Pentassuglia, L., Peng, X., Samaras, S., Davidson, J.M., Sawyer, D.B., and
Lim, C.C. (2012). Disruption of a GATA4/Ankrd1 signaling axis in cardiomyocytes leads to
sarcomere disarray: implications for anthracycline cardiomyopathy. PLoS One 7, e35743.
Chu, T.F., Rupnick, M.A., Kerkela, R., Dallabrida, S.M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E.,
Cassiola, F., Desai, J., George, S., Morgan, J.A., Harris, D.M., Ismail, N.S., Chen, J.H., Schoen, F.J.,
Van Den Abbeele, A.D., Demetri, G.D., Force, T., and Chen, M.H. (2007). Cardiotoxicity associated
with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019.
Cimetidine
(2018).
Cimetidine
tablet
Interview
Form
[Online].
Available:
http://www.info.pmda.go.jp/go/interview/1/530169_2325001F1530_1_006_1F [Accessed].
Cross, M.J., Berridge, B.R., Clements, P.J., Cove-Smith, L., Force, T.L., Hoffmann, P., Holbrook, M., Lyon, A.R.,
Mellor, H.R., Norris, A.A., Pirmohamed, M., Tugwood, J.D., Sidaway, J.E., and Park, B.K. (2015).
Physiological, pharmacological and toxicological considerations of drug-induced structural
cardiac injury. Br J Pharmacol 172, 957-974.
Del Rivero, J., Enewold, L., and Thomas, A. (2016). Metastatic lung cancer in the age of targeted therapy:
improving long-term survival. Transl Lung Cancer Res 5, 727-730.
Doherty, K.R., Talbert, D.R., Trusk, P.B., Moran, D.M., Shell, S.A., and Bacus, S. (2015). Structural and
functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately
identifies cardiotoxicity of multiple drug types. Toxicol Appl Pharmacol 285, 51-60.
Ewer, M.S., Suter, T.M., Lenihan, D.J., Niculescu, L., Breazna, A., Demetri, G.D., and Motzer, R.J. (2014).
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo:
a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility
of cardiac events. Eur J Cancer 50, 2162-2170.
Fan, F., He, Z., Kong, L.L., Chen, Q., Yuan, Q., Zhang, S., Ye, J., Liu, H., Sun, X., Geng, J., Yuan, L., Hong, L.,
Xiao, C., Zhang, W., Li, Y., Wang, P., Huang, L., Wu, X., Ji, Z., Wu, Q., Xia, N.S., Gray, N.S., Chen, L.,
Yun, C.H., Deng, X., and Zhou, D. (2016). Pharmacological targeting of kinases MST1 and MST2
augments tissue repair and regeneration. Sci Transl Med 8, 352ra108.
Fasudil (2010). Fasudil hydrochloride hydrate Interview form [Online]. Available: http://www.akhcc.com/product/file/product_interview/33 [Accessed].
Ferri, N., Siegl, P., Corsini, A., Herrmann, J., Lerman, A., and Benghozi, R. (2013). Drug attrition during preclinical and clinical development: understanding and managing drug-induced cardiotoxicity.
Pharmacol Ther 138, 470-484.
Fitzmaurice, C., Allen, C., Barber, R.M., Barregard, L., Bhutta, Z.A., Brenner, H., Dicker, D.J., Chimed-Orchir,
O., Dandona, R., Dandona, L., Fleming, T., Forouzanfar, M.H., Hancock, J., Hay, R.J., Hunter-Merrill,
R., Huynh, C., Hosgood, H.D., Johnson, C.O., Jonas, J.B., Khubchandani, J., Kumar, G.A., Kutz, M.,
77
Lan, Q., Larson, H.J., Liang, X., Lim, S.S., Lopez, A.D., Macintyre, M.F., Marczak, L., Marquez, N.,
Mokdad, A.H., Pinho, C., Pourmalek, F., Salomon, J.A., Sanabria, J.R., Sandar, L., Sartorius, B.,
Schwartz, S.M., Shackelford, K.A., Shibuya, K., Stanaway, J., Steiner, C., Sun, J., Takahashi, K.,
Vollset, S.E., Vos, T., Wagner, J.A., Wang, H., Westerman, R., Zeeb, H., Zoeckler, L., Abd-Allah, F.,
Ahmed, M.B., Alabed, S., Alam, N.K., Aldhahri, S.F., Alem, G., Alemayohu, M.A., Ali, R., Al-Raddadi,
R., Amare, A., Amoako, Y., Artaman, A., Asayesh, H., Atnafu, N., Awasthi, A., Saleem, H.B., Barac,
A., Bedi, N., Bensenor, I., Berhane, A., Bernabe, E., Betsu, B., Binagwaho, A., Boneya, D., CamposNonato, I., Castaneda-Orjuela, C., Catala-Lopez, F., Chiang, P., Chibueze, C., Chitheer, A., Choi, J.Y.,
Cowie, B., Damtew, S., Das Neves, J., Dey, S., Dharmaratne, S., Dhillon, P., Ding, E., Driscoll, T.,
Ekwueme, D., Endries, A.Y., Farvid, M., Farzadfar, F., Fernandes, J., Fischer, F., Tt, G.H., Gebru, A.,
Gopalani, S., Hailu, A., et al. (2017). Global, Regional, and National Cancer Incidence, Mortality,
Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer
Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol
3, 524-548.
Focaccetti, C., Bruno, A., Magnani, E., Bartolini, D., Principi, E., Dallaglio, K., Bucci, E.O., Finzi, G., Sessa, F.,
Noonan, D.M., and Albini, A. (2015). Effects of 5-fluorouracil on morphology, cell cycle,
proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes.
PLoS One 10, e0115686.
Force, T., Krause, D.S., and Van Etten, R.A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine
kinase inhibition. Nat Rev Cancer 7, 332-344.
Forsman, A., and Ohman, R. (1976). Pharmacokinetic studies on haloperidol in man. Curr Ther Res Clin Exp
20, 319-336.
Francis, G.S., Bartos, J.A., and Adatya, S. (2014). Inotropes. J Am Coll Cardiol 63, 2069-2078.
Gefitinib
(2005).
Gefitinib
tablets
Drugs@FDA
[Online].
Available:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021399s008lbl.pdf [Accessed].
Giza, D.E., Moudgil, R., Lopez-Mattei, J., Kim, P., and Iliescu, C. (2017). Association between ibrutinib and
mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced
Takostubo’s cardiomyopathy. Eur Heart J Case Reports 1, 1-7.
Glibenclamide (2017). Glibenclamide tablet Interview form [Online]. Available: https://chugaipharm.jp/hc/ss/pr/drug/eug_tab0125/if/PDF/eug_if.pdf?_back=1,1 [Accessed].
Hall, P.S., Harshman, L.C., Srinivas, S., and Witteles, R.M. (2013). The frequency and severity of
cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC
Heart Fail 1, 72-78.
Hirt, M.N., Hansen, A., and Eschenhagen, T. (2014). Cardiac tissue engineering: state of the art. Circ Res
114, 354-367.
Holden, J.K., and Cunningham, C.N. (2018). Targeting the Hippo Pathway and Cancer through the TEAD
78
Family of Transcription Factors. Cancers (Basel) 10.
Holmgren, G., Sartipy, P., Andersson, C.X., Lindahl, A., and Synnergren, J. (2018). Expression Profiling of
Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and
Visualization of Multi-Omics Data. Toxicol Sci 163, 182-195.
Hughes, J.P., Rees, S., Kalindjian, S.B., and Philpott, K.L. (2011). Principles of early drug discovery. Br J
Pharmacol 162, 1239-1249.
Jackson, T., Ditmanson, L., and Phibbs, B. (1997). Torsade de pointes and low-dose oral haloperidol. Arch
Intern Med 157, 2013-2015.
Jemal, A., Ward, E.M., Johnson, C.J., Cronin, K.A., Ma, J., Ryerson, B., Mariotto, A., Lake, A.J., Wilson, R.,
Sherman, R.L., Anderson, R.N., Henley, S.J., Kohler, B.A., Penberthy, L., Feuer, E.J., and Weir, H.K.
(2017). Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl
Cancer Inst 109.
Johnson, B.F., and Bye, C. (1975). Maximal intestinal absorption of digoxin, and its relation to steady state
plasma concentration. Br Heart J 37, 203-208.
Jones, R.L., Bendell, J.C., Smith, D.C., Diefenbach, K., Lettieri, J., Boix, O., Lockhart, A.C., O'bryant, C., and
Moore, K.N. (2015). A phase I open-label trial evaluating the cardiovascular safety of regorafenib
in patients with advanced cancer. Cancer Chemother Pharmacol 76, 777-784.
Kango-Singh, M., and Singh, A. (2009). Regulation of organ size: insights from the Drosophila Hippo
signaling pathway. Dev Dyn 238, 1627-1637.
Kedan, A., Verma, N., Saroha, A., Shreberk-Shaked, M., Muller, A.K., Nair, N.U., and Lev, S. (2018). PYK2
negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein. Cell Death Dis 9, 985.
Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S.,
Clubb, F.J., Rosenzweig, A., Salomon, R.N., Van Etten, R.A., Alroy, J., Durand, J.B., and Force, T.
(2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12, 908-916.
Khakoo, A.Y., Kassiotis, C.M., Tannir, N., Plana, J.C., Halushka, M., Bickford, C., Trent, J., 2nd, Champion, J.C.,
Durand, J.B., and Lenihan, D.J. (2008). Heart failure associated with sunitinib malate: a
multitargeted receptor tyrosine kinase inhibitor. Cancer 112, 2500-2508.
Kimura, A. (2011). Contribution of genetic factors to the pathogenesis of dilated cardiomyopathy: the
cause of dilated cardiomyopathy: genetic or acquired? (genetic-side). Circ J 75, 1756-1765;
discussion 1765.
Kostin, S. (2005). Pathways of myocyte death: implications for development of clinical laboratory
biomarkers. Adv Clin Chem 40, 37-98.
Kostin, S., Pool, L., Elsasser, A., Hein, S., Drexler, H.C., Arnon, E., Hayakawa, Y., Zimmermann, R., Bauer, E.,
Klovekorn, W.P., and Schaper, J. (2003). Myocytes die by multiple mechanisms in failing human
hearts. Circ Res 92, 715-724.
Koutsoukis, A., Ntalianis, A., Repasos, E., Kastritis, E., Dimopoulos, M.A., and Paraskevaidis, I. (2018).
79
Cardio-oncology: A Focus on Cardiotoxicity. Eur Cardiol 13, 64-69.
Lampson, B.L., Yu, L., Glynn, R.J., Barrientos, J.C., Jacobsen, E.D., Banerji, V., Jones, J.A., Walewska, R.,
Savage, K.J., Michaud, G.F., Moslehi, J.J., and Brown, J.R. (2017). Ventricular arrhythmias and
sudden death in patients taking ibrutinib. Blood 129, 2581-2584.
Langhans, S.A. (2018). Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug
Repositioning. Front Pharmacol 9, 6.
Lenneman, C.G., and Sawyer, D.B. (2016). Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related
Treatment. Circ Res 118, 1008-1020.
Lim, C.C., Zuppinger, C., Guo, X., Kuster, G.M., Helmes, M., Eppenberger, H.M., Suter, T.M., Liao, R., and
Sawyer, D.B. (2004). Anthracyclines induce calpain-dependent titin proteolysis and necrosis in
cardiomyocytes. J Biol Chem 279, 8290-8299.
Liu, R., Jagannathan, R., Sun, L., Li, F., Yang, P., Lee, J., Negi, V., Perez-Garcia, E.M., Shiva, S., Yechoor, V.K.,
and Moulik, M. (2020). Tead1 is essential for mitochondrial function in cardiomyocytes. Am J
Physiol Heart Circ Physiol 319, H89-H99.
Liu, R., Lee, J., Kim, B.S., Wang, Q., Buxton, S.K., Balasubramanyam, N., Kim, J.J., Dong, J., Zhang, A., Li, S.,
Gupte, A.A., Hamilton, D.J., Martin, J.F., Rodney, G.G., Coarfa, C., Wehrens, X.H., Yechoor, V.K.,
and Moulik, M. (2017). Tead1 is required for maintaining adult cardiomyocyte function, and its
loss results in lethal dilated cardiomyopathy. JCI Insight 2.
Ma, J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J.A., Kamp, T.J., Kolaja, K.L., Swanson, B.J., and January,
C.T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes:
electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ
Physiol 301, H2006-2017.
Macedo, A.V.S., Hajjar, L.A., Lyon, A.R., Nascimento, B.R., Putzu, A., Rossi, L., Costa, R.B., Landoni, G.,
Nogueira-Rodrigues, A., and Ribeiro, A.L.P. (2019). Efficacy of Dexrazoxane in Preventing
Anthracycline Cardiotoxicity in Breast Cancer. JACC CardioOncol 1, 68-79.
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M.,
Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T.,
Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., and Nukiwa, T. (2010).
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362,
2380-2388.
Martin, H.L., Adams, M., Higgins, J., Bond, J., Morrison, E.E., Bell, S.M., Warriner, S., Nelson, A., and
Tomlinson, D.C. (2014). High-content, high-throughput screening for the identification of
cytotoxic compounds based on cell morphology and cell proliferation markers. PLoS One 9,
e88338.
Matsui, T., and Shinozawa, T. (2021). Human Organoids for Predictive Toxicology Research and Drug
Development. Front Genet 12, 767621.
80
Mcgowan, J.V., Chung, R., Maulik, A., Piotrowska, I., Walker, J.M., and Yellon, D.M. (2017). Anthracycline
Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther 31, 63-75.
Mcneil, J.J., Mihaly, G.W., Anderson, A., Marshall, A.W., Smallwood, R.A., and Louis, W.J. (1981).
Pharmacokinetics of the H2- receptor antagonist ranitidine in man. Br J Clin Pharmacol 12, 411415.
Mia, M.M., and Singh, M.K. (2019). The Hippo Signaling Pathway in Cardiac Development and Diseases.
Front Cell Dev Biol 7, 211.
Mordwinkin, N.M., Burridge, P.W., and Wu, J.C. (2013). A review of human pluripotent stem cell-derived
cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication
standards. J Cardiovasc Transl Res 6, 22-30.
Mortensen, S.A., Olsen, H.S., and Baandrup, U. (1986). Chronic anthracycline cardiotoxicity:
haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial
disease. Br Heart J 55, 274-282.
Nilotinib
(2018).
Nilotinib
Capsules
Interview
form
[Online].
Available:
https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tasigna.pdf
[Accessed].
Ohashi, K., Ebihara, A., Kondo, K., and Usami, M. (1984). Clinical pharmacokinetics and pharmacological
actions of a long-acting formulation of propranolol. Arzneimittelforschung 34, 507-512.
Perez, I.E., Taveras Alam, S., Hernandez, G.A., and Sancassani, R. (2019). Cancer Therapy-Related Cardiac
Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol 13, 1179546819866445.
Pincus, M. (2016). Management of digoxin toxicity. Aust Prescr 39, 18-20.
Pointon, A., Abi-Gerges, N., Cross, M.J., and Sidaway, J.E. (2013). Phenotypic profiling of structural
cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicol Sci 132, 317326.
Pointon, A., Pilling, J., Dorval, T., Wang, Y., Archer, C., and Pollard, C. (2017). From the Cover: HighThroughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during
Drug Discovery. Toxicol Sci 155, 444-457.
Pravastatin (2018). Pravastatin DrugBank.
Pun, S.C., and Neilan, T.G. (2016). Cardiovascular side effects of small molecule therapies for cancer. Eur
Heart J 37, 2742-2745.
Regorafenib
(2012).
Regorafenib
tablets
Interview
form
[Online].
Available:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf [Accessed].
Ronaldson-Bouchard, K., and Vunjak-Novakovic, G. (2018). Organs-on-a-Chip: A Fast Track for Engineered
Human Tissues in Drug Development. Cell Stem Cell 22, 310-324.
Roskoski, R., Jr. (2007). Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
Biochem Biophys Res Commun 356, 323-328.
81
Santos, F.P., and Cortes, J. (2012). Dasatinib for the treatment of Philadelphia chromosome-positive
leukemias. Expert Opin Pharmacother 13, 2381-2395.
Santos Mateo, J.J., Sabater Molina, M., and Gimeno Blanes, J.R. (2018). Hypertrophic cardiomyopathy.
Med Clin (Barc) 150, 434-442.
Sawyer, D.B., Zuppinger, C., Miller, T.A., Eppenberger, H.M., and Suter, T.M. (2002). Modulation of
anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and
anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105, 15511554.
Scheffel, R.S., Dora, J.M., Siqueira, D.R., Burttet, L.M., Cerski, M.R., and Maia, A.L. (2013). Toxic
cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with
histopathological analysis. Eur J Endocrinol 168, K51-54.
Schmidinger, M., Zielinski, C.C., Vogl, U.M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., and
Schmidinger, H. (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic
renal cell carcinoma. J Clin Oncol 26, 5204-5212.
Sequeira, V., Nijenkamp, L.L., Regan, J.A., and Van Der Velden, J. (2014). The physiological role of cardiac
cytoskeleton and its alterations in heart failure. Biochim Biophys Acta 1838, 700-722.
Shah, R.R., and Morganroth, J. (2015). Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With
a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit. Drug Saf 38,
693-710.
Sharma, A., Burridge, P.W., Mckeithan, W.L., Serrano, R., Shukla, P., Sayed, N., Churko, J.M., Kitani, T., Wu,
H., Holmstrom, A., Matsa, E., Zhang, Y., Kumar, A., Fan, A.C., Del Alamo, J.C., Wu, S.M., Moslehi,
J.J., Mercola, M., and Wu, J.C. (2017). High-throughput screening of tyrosine kinase inhibitor
cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med 9.
Shinozawa, T., Furukawa, H., Sato, E., and Takami, K. (2012). A novel purification method of murine
embryonic stem cell- and human-induced pluripotent stem cell-derived cardiomyocytes by
simple manual dissociation. J Biomol Screen 17, 683-691.
Shroff, R.T., Yarchoan, M., O'connor, A., Gallagher, D., Zahurak, M.L., Rosner, G., Ohaji, C., SartoriusMergenthaler, S., Parkinson, R., Subbiah, V., Zinner, R., and Azad, N.S. (2017). The oral VEGF
receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in
advanced cholangiocarcinoma. Br J Cancer 116, 1402-1407.
Singh, S., Carpenter, A.E., and Genovesio, A. (2014). Increasing the Content of High-Content Screening: An
Overview. J Biomol Screen 19, 640-650.
Sirenko, O., Hesley, J., Rusyn, I., and Cromwell, E.F. (2014). High-content assays for hepatotoxicity using
induced pluripotent stem cell-derived cells. Assay Drug Dev Technol 12, 43-54.
Smoot, R.L., Werneburg, N.W., Sugihara, T., Hernandez, M.C., Yang, L., Mehner, C., Graham, R.P., Bronk,
S.F., Truty, M.J., and Gores, G.J. (2018). Platelet-derived growth factor regulates YAP
82
transcriptional activity via Src family kinase dependent tyrosine phosphorylation. J Cell Biochem
119, 824-836.
Swain, S.M., Whaley, F.S., and Ewer, M.S. (2003). Congestive heart failure in patients treated with
doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869-2879.
Teerlink, J.R., Metra, M., Zaca, V., Sabbah, H.N., Cotter, G., Gheorghiade, M., and Cas, L.D. (2009). Agents
with inotropic properties for the management of acute heart failure syndromes. Traditional
agents and beyond. Heart Fail Rev 14, 243-253.
Triastuti, E., Nugroho, A.B., Zi, M., Prehar, S., Kohar, Y.S., Bui, T.A., Stafford, N., Cartwright, E.J., Abraham,
S., and Oceandy, D. (2019). Pharmacological inhibition of Hippo pathway, with the novel kinase
inhibitor XMU-MP-1, protects the heart against adverse effects during pressure overload. Br J
Pharmacol 176, 3956-3971.
Wallace, N., Wong, E., Cooper, D., and Chao, H. (2016). A case of new-onset cardiomyopathy and
ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma. Clin
Case Rep 4, 1120-1121.
Wang, J., Liu, S., Heallen, T., and Martin, J.F. (2018). The Hippo pathway in the heart: pivotal roles in
development, disease, and regeneration. Nat Rev Cardiol 15, 672-684.
Weinberger, F., Mannhardt, I., and Eschenhagen, T. (2017). Engineering Cardiac Muscle Tissue: A
Maturating Field of Research. Circ Res 120, 1487-1500.
Willis, M.S., Schisler, J.C., Portbury, A.L., and Patterson, C. (2009). Build it up-Tear it down: protein quality
control in the cardiac sarcomere. Cardiovasc Res 81, 439-448.
Wilson, M.S., Graham, J.R., and Ball, A.J. (2014). Multiparametric High Content Analysis for assessment of
neurotoxicity in differentiated neuronal cell lines and human embryonic stem cell-derived
neurons. Neurotoxicology 42, 33-48.
Yeh, E.T., and Bickford, C.L. (2009). Cardiovascular complications of cancer therapy: incidence,
pathogenesis, diagnosis, and management. J Am Coll Cardiol 53, 2231-2247.
Zamorano, J.L., Lancellotti, P., Rodriguez Munoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G.,
Lenihan, D.J., Lip, G.Y.H., Lyon, A.R., Lopez Fernandez, T., Mohty, D., Piepoli, M.F., Tamargo, J.,
Torbicki, A., Suter, T.M., and Group, E.S.C.S.D. (2016). 2016 ESC Position Paper on cancer
treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for
Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the
European Society of Cardiology (ESC). Eur Heart J 37, 2768-2801.
Zhang, J., Wilson, G.F., Soerens, A.G., Koonce, C.H., Yu, J., Palecek, S.P., Thomson, J.A., and Kamp, T.J. (2009).
Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104, e3041.
Zuppinger, C. (2016). 3D culture for cardiac cells. Biochim Biophys Acta 1863, 1873-1881.
83
...
論文の公開元へ
